On September 16, WUXI BIO rose 3.21% in regular trading, trading at HK$50.8/share, with turnover of HK$257 million. The stock advanced alongside a broad-based rally in the CXO sector, as mid-year earnings continued to validate elevated industry prosperity.

Multiple CXO peers posted notable gains on the same session, with PHARMARON up 3.95%, GENSCRIPT BIO up 2.96%, and WUXI APPTEC up 2.47%, reflecting strong sector linkage. The rally extends a wave of momentum triggered by first-half results across the industry. WUXI BIO itself reported H1 revenue of RMB 11.787 billion, up 18.4% year-over-year, with adjusted net profit attributable to shareholders surging 38.4%. The company raised its full-year revenue growth guidance to 15%-18% and disclosed an unfilled order backlog of approximately US$5.5 billion, up around 30% year-over-year.

Several major brokerages have recently lifted their target prices for the company, with CICC, CMBI, and Daiwa all setting targets near HK$59-60. Additionally, the emerging commercialization of AI-driven drug discovery is seen as opening further mid-to-long-term growth potential for leading CXO companies actively integrating AI capabilities into their platforms.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)